US7252989B1
(en)
*
|
1994-04-04 |
2007-08-07 |
Board Of Regents, The University Of Texas System |
Adenovirus supervector system
|
US20060110798A1
(en)
*
|
1995-06-07 |
2006-05-25 |
Graham Frank L |
Cells expressing recombinase useful for adenovirus vector production and control of gene expression
|
US7232899B2
(en)
|
1996-09-25 |
2007-06-19 |
The Scripps Research Institute |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
US6403370B1
(en)
|
1997-02-10 |
2002-06-11 |
Genstar Therapeutics Corporation |
Oncolytic/immunogenic complementary-adenoviral vector system
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
CN1342206A
(zh)
|
1998-08-28 |
2002-03-27 |
杜克大学 |
在IVa2,100K和/或preterminal protein序列上有缺失的腺病毒
|
AU772630B2
(en)
*
|
1999-01-14 |
2004-05-06 |
Novartis Ag |
Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
|
JP2000279178A
(ja)
*
|
1999-02-24 |
2000-10-10 |
Japan Found Cancer Res |
ウイルスベクター
|
US6492169B1
(en)
*
|
1999-05-18 |
2002-12-10 |
Crucell Holland, B.V. |
Complementing cell lines
|
JP2003502058A
(ja)
*
|
1999-06-11 |
2003-01-21 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
48個のヒト分泌タンパク質
|
DE60038971D1
(de)
|
1999-10-22 |
2008-07-03 |
Aventis Pasteur |
Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
|
WO2001034825A1
(en)
*
|
1999-11-10 |
2001-05-17 |
Genzyme Corporation |
Ptp/dna polymerase cell line as packaging cell line for minimal adenoviral vectors
|
WO2001044280A2
(en)
*
|
1999-12-14 |
2001-06-21 |
Genovo, Inc. |
Methods and compositions for the manufacture of replication incompetent adenovirus
|
US6867022B1
(en)
*
|
2000-01-21 |
2005-03-15 |
Regents Of The University Of Michigan |
Replication deficient adenovirus vectors and methods of making and using them
|
US6562955B2
(en)
*
|
2000-03-17 |
2003-05-13 |
Tosoh Corporation |
Oligonucleotides for detection of Vibrio parahaemolyticus and detection method for Vibrio parahaemolyticus using the same oligonucleotides
|
AU2001261063A1
(en)
*
|
2000-04-28 |
2001-11-12 |
Xiao Xiao |
Dna sequences encoding dystrophin minigenes and methods of use thereof
|
EP1282702B1
(de)
|
2000-05-10 |
2006-11-29 |
Sanofi Pasteur Limited |
Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US7125549B2
(en)
*
|
2000-05-31 |
2006-10-24 |
Human Gene Therapy Research Institute |
Methods and compositions for efficient gene transfer using transcomplementary vectors
|
DE60130465T2
(de)
*
|
2000-07-14 |
2008-06-12 |
The Regents Of The University Of Michigan, Ann Arbor |
Mutierte muskelspezifische enhancer
|
US6852323B2
(en)
|
2000-07-21 |
2005-02-08 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
US7223406B2
(en)
*
|
2000-07-21 |
2007-05-29 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
US8044259B2
(en)
|
2000-08-03 |
2011-10-25 |
The Regents Of The University Of Michigan |
Determining the capability of a test compound to affect solid tumor stem cells
|
US6984522B2
(en)
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US20080194022A1
(en)
*
|
2000-08-03 |
2008-08-14 |
Clarke Michael F |
Isolation and use of solid tumor stem cells
|
EP1320620B1
(de)
*
|
2000-09-25 |
2015-01-21 |
The Regents Of The University Of Michigan |
Herstellung viraler vektoren
|
GB2368064B
(en)
|
2000-09-30 |
2002-11-13 |
Imp Cancer Res Tech |
DNA Element and Associated Protein
|
US6916635B2
(en)
*
|
2000-10-02 |
2005-07-12 |
The Research Foundation Of State University Of New York |
Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
|
JP2004525368A
(ja)
|
2001-03-07 |
2004-08-19 |
ザ・テキサス・エイ・アンド・エム・ユニバーシテイ・システム |
金属イオンキレート錯体の密度勾配溶液
|
WO2002072790A2
(en)
|
2001-03-14 |
2002-09-19 |
Myriad Genetics, Inc |
Tsg101-gag interaction and use thereof
|
JP2004532039A
(ja)
*
|
2001-03-26 |
2004-10-21 |
ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ |
ヘルパー依存性アデノウイルスベクター系およびその系の使用方法
|
US20030138405A1
(en)
*
|
2001-04-17 |
2003-07-24 |
Juan Fueyo |
Conditionally replicative adenovirus to target the Rb and Rb-related pathways
|
US6844192B2
(en)
|
2001-06-29 |
2005-01-18 |
Wake Forest University |
Adenovirus E4 protein variants for virus production
|
WO2003002746A2
(en)
*
|
2001-06-29 |
2003-01-09 |
Novartis Ag |
Perv screening method and use thereof
|
US20030021768A1
(en)
*
|
2001-07-23 |
2003-01-30 |
Yuqiao Shen |
Viral mutants that selectively replicate in targeted human cancer cells
|
US7229774B2
(en)
|
2001-08-02 |
2007-06-12 |
Regents Of The University Of Michigan |
Expression profile of prostate cancer
|
DE10150984A1
(de)
*
|
2001-10-16 |
2003-04-17 |
Holm Per Sonne |
Verwendung des adenoviralen E2-late-Promotors
|
WO2003033723A2
(en)
*
|
2001-10-18 |
2003-04-24 |
Aventis Pharmaceuticals Inc. |
Vectors for expressing multiple transgenes
|
EP1308517A1
(de)
*
|
2001-10-31 |
2003-05-07 |
Aventis Pharmacueticals Products Inc. |
Vektoren für die Expression von mehrere Transgenen
|
US20030165954A1
(en)
|
2002-01-09 |
2003-09-04 |
Third Wave Technologies, Inc. |
Cancer profiles
|
EP1864691B1
(de)
|
2002-04-09 |
2011-07-20 |
Sanofi Pasteur Limited |
Modifizierte CEA-Nukleinsäure und entsprechende Expressionsvektoren
|
US20030219696A1
(en)
*
|
2002-05-23 |
2003-11-27 |
Moreland Gerald W. |
Method and apparatus for preventing backflow in dental saliva evacuators
|
KR101083450B1
(ko)
|
2002-05-27 |
2011-11-16 |
페르 손네 홀름 |
아데노바이러스 및 그를 코딩하는 핵산의 신규 용도
|
US7803365B2
(en)
*
|
2002-12-02 |
2010-09-28 |
Biovec, Llc |
Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
|
US9388427B2
(en)
|
2002-12-02 |
2016-07-12 |
Biovec, Llc |
In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors
|
AU2003298768A1
(en)
*
|
2002-12-02 |
2004-06-23 |
Biovec Llc |
Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases
|
CA2511521C
(en)
|
2002-12-30 |
2012-02-07 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
CA2515916A1
(en)
*
|
2003-02-25 |
2004-09-10 |
Biovec B.V. |
Therapeutic applications of thrombomodulin gene via viral and non-viral vectors
|
CA2528669A1
(en)
|
2003-06-09 |
2005-01-20 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
ATE500267T1
(de)
|
2003-07-21 |
2011-03-15 |
Transgene Sa |
Multifunktionelle cytokine
|
CA2550583C
(en)
*
|
2003-10-08 |
2013-01-15 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
CA2546178A1
(en)
|
2003-11-14 |
2005-06-09 |
Per Sonne Holm |
New use of adenovirus and nucleic acids coding therefor
|
WO2005086922A2
(en)
|
2004-03-10 |
2005-09-22 |
Board Of Regents, University Of Texas System |
Oncolytic adenovirus armed with therapeutic genes
|
US8470315B2
(en)
|
2004-04-13 |
2013-06-25 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
US20080305181A1
(en)
*
|
2004-04-20 |
2008-12-11 |
Kontos Christopher D |
Compositions and Methods for Treatment of Vascular Grafts
|
US7858323B2
(en)
|
2004-06-09 |
2010-12-28 |
The Regents Of The University Of Michigan |
Phage microarray profiling of the humoral response to disease
|
JP2008515908A
(ja)
|
2004-10-06 |
2008-05-15 |
ユニバーシティー オブ ロチェスター |
組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療
|
KR100984602B1
(ko)
*
|
2004-11-18 |
2010-09-30 |
고쿠리츠다이가쿠호진 히로시마다이가쿠 |
유전자 증폭에 의해 형성된 반복서열로부터, 발현이 억제된단백질을 발현시키는 방법, 키트, 및 형질전환체
|
US8557969B2
(en)
*
|
2004-12-01 |
2013-10-15 |
The Regents Of The University Of Michigan |
Compositions and methods for regulating cardiac performance
|
CA2595407A1
(en)
|
2005-01-20 |
2006-07-27 |
University Of Rochester |
Thioredoxin interacting protein (txnip) as regulator of vascular function
|
EP1907858A4
(de)
*
|
2005-06-13 |
2009-04-08 |
Univ Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
|
AU2006291054B2
(en)
|
2005-09-12 |
2011-10-13 |
The Brigham And Women's Hospital, Inc. |
Recurrent gene fusions in prostate cancer
|
US8652467B2
(en)
*
|
2005-10-14 |
2014-02-18 |
The Regents Of The University Of Michigan |
Dek protein compositions and methods of using the same
|
US7794951B2
(en)
*
|
2005-10-18 |
2010-09-14 |
University Of Massachusetts Medical School |
SREBP2gc transcription factors and uses thereof
|
AU2006344359B2
(en)
|
2005-10-31 |
2013-08-15 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
US7723477B2
(en)
|
2005-10-31 |
2010-05-25 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
|
AU2006308847C1
(en)
*
|
2005-10-31 |
2012-05-10 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for treating and diagnosing cancer
|
US8840882B2
(en)
*
|
2006-06-23 |
2014-09-23 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
EP2041311A4
(de)
|
2006-06-23 |
2010-07-07 |
Myriad Genetics Inc |
Varianten des dpyd-gens und ihre verwendung
|
US8298801B2
(en)
|
2006-07-17 |
2012-10-30 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
WO2008030605A2
(en)
*
|
2006-09-08 |
2008-03-13 |
The Regents Of The University Of Michigan |
Herv group ii viruses in lymphoma and cancer
|
WO2008108890A2
(en)
*
|
2006-10-18 |
2008-09-12 |
University Of Rochester |
Conditionally replicating viruses for cancer therapy
|
EP2106439B1
(de)
|
2007-01-24 |
2014-11-12 |
The Regents of the University of Michigan |
Zusammensetzungen und verfahren zur behandlung und diagnostizierung von pankreaskrebs
|
US10745701B2
(en)
|
2007-06-28 |
2020-08-18 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
US20090324596A1
(en)
|
2008-06-30 |
2009-12-31 |
The Trustees Of Princeton University |
Methods of identifying and treating poor-prognosis cancers
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
EP3018216B1
(de)
|
2007-07-06 |
2018-09-12 |
The Regents Of The University Of Michigan |
Rezidivierende genfusionen bei prostatakrebs
|
CA2695674A1
(en)
|
2007-08-16 |
2009-02-26 |
Metabolon, Inc. |
Metabolomic profiling of prostate cancer
|
EP2205271B1
(de)
*
|
2007-10-08 |
2014-05-21 |
Quintessence Biosciences, Inc. |
Zusammensetzungen und verfahren für therapien auf ribonukleasebasis
|
US8193151B2
(en)
*
|
2008-04-25 |
2012-06-05 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias
|
US8518884B2
(en)
|
2008-04-25 |
2013-08-27 |
Northwestern University |
Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
|
WO2010037041A2
(en)
|
2008-09-26 |
2010-04-01 |
Oncomed Pharmaceuticals, Inc. |
Frizzled-binding agents and uses thereof
|
EP2334695B1
(de)
|
2008-10-01 |
2015-12-23 |
Quintessence Biosciences, Inc. |
Therapeutische ribonukleasen
|
CN102639709A
(zh)
|
2009-01-09 |
2012-08-15 |
密歇根大学董事会 |
癌症中的复现性基因融合体
|
WO2010107991A2
(en)
|
2009-03-18 |
2010-09-23 |
Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
|
EA032675B1
(ru)
|
2009-06-10 |
2019-07-31 |
Нью-Йорк Юниверсити |
Способ и композиции для лечения болезни альцгеймера и других таупатий
|
TWI535445B
(zh)
|
2010-01-12 |
2016-06-01 |
安可美德藥物股份有限公司 |
Wnt拮抗劑及治療和篩選方法
|
WO2011116209A2
(en)
|
2010-03-17 |
2011-09-22 |
The Regents Of The University Of Michigan |
Using phage epitopes to profile the immune response
|
JP2013530929A
(ja)
|
2010-04-01 |
2013-08-01 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
frizzled結合剤およびその使用
|
US20130344053A1
(en)
|
2010-12-28 |
2013-12-26 |
University Of Rochester |
Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides
|
US20140155469A1
(en)
|
2011-04-19 |
2014-06-05 |
The Research Foundation Of State University Of New York |
Adeno-associated-virus rep sequences, vectors and viruses
|
WO2013001372A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of Oslo |
Methods and compositions for inhibition of activation of regulatory t cells
|
RS55088B1
(sr)
|
2011-07-06 |
2016-12-30 |
Sykehuset Sorlandet Hf |
Egfr ciljana terapija
|
HUE051021T2
(hu)
|
2011-09-07 |
2021-01-28 |
Sinai School Medicine |
Ceramidáz és sejtek differenciálódása
|
US9265813B2
(en)
|
2011-10-27 |
2016-02-23 |
Wellstat Ophthalmics Corporation |
Vectors encoding rod-derived cone viability factor
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
US9694050B2
(en)
|
2012-10-21 |
2017-07-04 |
University Of Rochester |
THY1 (CD90) as a novel therapy to control adipose tissue accumulation
|
WO2014066443A1
(en)
|
2012-10-23 |
2014-05-01 |
Emory University |
Gm-csf and il-4 conjugates, compositions, and methods related thereto
|
JP2015536933A
(ja)
|
2012-10-23 |
2015-12-24 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
|
AU2013362134B2
(en)
|
2012-12-21 |
2018-07-05 |
Sykehuset Sorlandet Hf |
EGFR targeted therapy of neurological disorders and pain
|
AU2014212081A1
(en)
|
2013-02-04 |
2015-08-13 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a Wnt pathway inhibitor
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
EP2992112B1
(de)
|
2013-04-22 |
2020-06-03 |
Icahn School of Medicine at Mount Sinai |
Mutationen in pdgfrb und notch3 als ursachen für autosomale dominante infantile myofibromatose
|
US10980896B2
(en)
|
2013-10-29 |
2021-04-20 |
President And Fellows Of Harvard College |
Methods and compositions for inhibiting oxidative stress
|
AU2016205215B2
(en)
|
2015-01-09 |
2021-03-11 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
KR20170102002A
(ko)
|
2015-01-09 |
2017-09-06 |
이투빅스 코포레이션 |
에볼라 바이러스 백신접종을 위한 방법 및 조성물
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
EP3371211A4
(de)
|
2015-11-04 |
2019-08-21 |
Icahn School of Medicine at Mount Sinai |
Verfahren zur behandlung von tumoren und krebs sowie identifizierung von kandidatenpatienten für solch eine behandlung
|
US10377801B2
(en)
|
2015-11-04 |
2019-08-13 |
Northwestern University |
Amelioration of chronic kidney disease
|
US10669320B2
(en)
|
2015-11-18 |
2020-06-02 |
The Regents Of The University Of Michigan |
Mps1 and KNL1 phosphorylation system
|
JP2019504631A
(ja)
*
|
2016-02-05 |
2019-02-21 |
ナント ホールディングス アイピー、エルエルシー |
組換えcxadr発現のための組成物および方法
|
EP3448881B1
(de)
|
2016-04-26 |
2023-06-07 |
Icahn School of Medicine at Mount Sinai |
Behandlung von hippo-pfad-mutanten tumoren und verfahren zur identifizierung von probanden als kandidaten für die behandlung
|
US20200282032A1
(en)
|
2016-05-27 |
2020-09-10 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
CA2971303A1
(en)
|
2016-06-21 |
2017-12-21 |
Bamboo Therapeutics, Inc. |
Optimized mini-dystrophin genes and expression cassettes and their use
|
US11091795B2
(en)
|
2016-07-11 |
2021-08-17 |
Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for diagnosing and treating arrhythmias
|
US11241436B2
(en)
|
2017-01-25 |
2022-02-08 |
Northwestern University |
Autophagy inducers for treatment of CNS conditions
|
EP3714043A4
(de)
|
2017-11-22 |
2021-08-11 |
The Regents of The University of Michigan |
Zusammensetzungen und verfahren zur behandlung von krebs
|
EP3743102A1
(de)
|
2018-01-26 |
2020-12-02 |
Nantcell, Inc. |
Zusammensetzungen und verfahren zur kombination eines krebsimpfstoffs und einer immunologischen adjuvanten therapie
|
WO2019147921A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Rapid verification of virus particle production for a personalized vaccine
|
US20220184232A1
(en)
*
|
2019-03-25 |
2022-06-16 |
The Regents Of The University Of California |
Methods of treating tnni3-mediated cardiomyopathy
|
CA3140019A1
(en)
*
|
2019-05-30 |
2020-12-03 |
Gritstone Bio, Inc. |
Modified adenoviruses
|
WO2020263463A1
(en)
|
2019-06-28 |
2020-12-30 |
Immunitybio, Inc. |
Pharmaceutical compositions to enhance phagocytosis without inflammation
|
KR102371663B1
(ko)
*
|
2020-01-21 |
2022-03-04 |
코오롱생명과학 주식회사 |
아데노바이러스 벡터
|
EP4118109A1
(de)
|
2020-03-11 |
2023-01-18 |
NantCell, Inc. |
Proteinöse therapeutika
|
JP2023520610A
(ja)
*
|
2020-03-28 |
2023-05-17 |
グレフェックス, インコーポレイテッド |
真核細胞におけるdna断片の維持、手法、および使用
|
WO2021211691A1
(en)
|
2020-04-14 |
2021-10-21 |
Immunitybio, Inc. |
Yeast lysate covid-19 vaccine
|
US20220047645A1
(en)
|
2020-08-11 |
2022-02-17 |
Musculoskeletal Transplant Foundation |
Method for treating cardiac conditions with placenta-dervived compositions
|
WO2022034523A1
(en)
|
2020-08-13 |
2022-02-17 |
Immunitybio, Inc. |
Phagocytosis-inducing compounds and methods of use
|
WO2023010047A1
(en)
|
2021-07-29 |
2023-02-02 |
Nantcell, Inc. |
Modified t cell receptors for the prevention and treatment of viral infections and cancer
|
EP4335870A1
(de)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptidtherapeutika gegen das sars-cov-2-spike-protein
|